

January 10, 2025

To
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Bandra Kurla Complex,
Mumbai-400051

Scrip: ONYX

Dear Sir/ Madam,

Sub: Outcome of the Board Meeting – Unaudited Standalone Financial Results for the Half Year ended September 30, 2024

Further to our letter dated January 4, 2025 and pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today January 10, 2025, inter-alia, considered and approved the Unaudited Standalone Financial Results for the half year ended September 30, 2024.

In this regard, we are enclosing herewith:

1. The Unaudited Standalone Financial Results of the Company for the half year ended September 30, 2024;
2. The Limited Review Report on Unaudited Standalone Financial Results of the Company for the half year ended September 30, 2024. A copy of the same is enclosed herewith.

The Unaudited Standalone financial results will be available on the Company's website i.e. www.onyxbiotec.com and on the website of the Stock Exchanges, <https://www.nseindia.com/>.

The meeting commenced at 3.00 p.m. and concluded at 3.40 p.m.

We request you to kindly take the above on records

For Onyx Biotech Limited



Sanjay Jain
Managing Director
DIN: 02214242

**Sanjay
Jain**

Digitally signed
by Sanjay Jain
Date: 2025.01.10
15:57:21 +05'30'

CIN- L24230HP2005PLC028403

R C A AND CO LLP

CHARTERED ACCOUNTANTS

SCO A-14, First Floor, Commercial Pocket A, Wave Estate,
Sector 85, Mohali - 140308

Mobile: +91 99155 95590 | Email: carajatbansal35@gmail.com



LIMITED REVIEW REPORT

To,
The Board of Directors
Onyx Biotec Limited

Sub: Limited Review Report on the Unaudited Standalone Financial Results for the Half year ended on September 30, 2024.

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Onyx Biotec Limited "the Company"** for the half year ended September 30, 2024, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with relevant Circulars issued by SEBI from time to time.
2. This statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information" Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R C A AND CO LLP

Firm Registration Number: 011602N/N500350

Chartered Accountants

Rajat Bansal
Rajat Bansal
Partner

Membership Number: 841482



UDIN: **25541484 BMM KA H 4089**

Place of the Signature: Chandigarh

Date: 10 January 2025

ONYX BIOTEC LIMITED

Regd Office: VILLAGE BIR PLASSI, NEAR SAINIMAJRAROPAR, NALAGRH ROAD, Solan, Himachal Pradesh, India, 174101


Website: <https://www.onyxbiotec.com/>, Email: generalinfo@onyxbiotech.com

CIN - L24230HP2005PLC028403

Standalone Statement of Assets and Liabilities

Particulars	(Rs. in Lakhs)	
	As at <u>Sep 30, 2024</u> <u>Unaudited</u>	As at <u>Mar 31, 2024</u> <u>Audited</u>
EQUITY & LIABILITIES		
1. Shareholder's Fund		
(a) Share Capital	1,332.22	1,332.22
(b) Reserves & Surplus	1,495.13	1,196.57
	<u>2,827.35</u>	<u>2,528.79</u>
2. Share Application Money pending Allotment	-	-
3. Non Current Liabilities		
(a) Long Term Borrowings	1,784.70	2,359.09
(b) Deferred Tax Liabilities (Net)	296.92	271.12
(c) Other Long Term Liabilities	-	-
(d) Long Term Provision	-	-
	<u>2,081.62</u>	<u>2,630.21</u>
4. Current Liabilities		
(a) Short Term Borrowings	1,231.75	718.95
(b) Trade Payables		
(i) total outstanding dues of micro enterprises and small enterprises; and	301.98	675.98
(ii) total outstanding dues of creditors other than micro enterprises and small enterprises	1,080.26	702.58
(c) Other Current Liabilities	175.05	129.77
(d) Short Term Provisions	81.00	27.31
	<u>2,870.03</u>	<u>2,254.58</u>
TOTAL	<u>7,779.01</u>	<u>7,413.58</u>
<u>ASSETS</u>		
1. Non-Current Assets		
(a) Property, Plant & Equipments and Intangible Assets		
(i) Property, Plant & Equipments	4,191.23	4,347.72
(ii) Intangible Assets	-	-
(iii) Capital Work in Progress	-	-
(iv) Intangible Assets under Development	-	-
(b) Non-current investments	-	-
(c) Deferred Tax Assets	-	-
(d) Long Term Loans & Advances	-	-
(e) Other Non Current Assets	114.12	110.03
	<u>4,305.35</u>	<u>4,457.75</u>
2. Current Assets		
(a) Current Investments		
(b) Inventories	1,185.41	910.31
(c) Trade Receivable	1,825.36	1,537.28
(d) Cash & Cash Equivalents	151.82	146.68
(e) Short Term Loans & Advances	14.50	27.64
(f) Other Current Assets	296.59	333.93
	<u>3,473.67</u>	<u>2,955.83</u>
	<u>7,779.01</u>	<u>7,413.58</u>

For and on behalf of the Board of Directors
Onyx Biotec Limited



Sanjay Jain
(Managing Director)
DIN: 02214242

Date: 10 January, 2025
Place: Chandigarh

ONYX BIOTEC LIMITED

Regd Office: VILLAGE BIR PLASSI, NEAR SAINIMAJRAROPAR, NALAGRH ROAD, Solan, Himachal Pradesh, India, 174101


Website: <https://www.onyxbiotech.com/>, Email: generalinfo@onyxbiotech.com**CIN - L24230HP2005PLC028403****Standalone Financial Results for the Half Year ended September 30, 2024**

(Rs. in Lakhs)

Particulars	Half Year Ended		Year Ended	
	30.09.24	31.03.24	30.09.23	31.03.24
	Unaudited	Unaudited	Unaudited	Audited
1. Income:				
(a) Revenue From Operation	3,014.95	2,985.79	2,389.09	5,374.88
(b) Other Income	98.71	8.86	3.69	12.55
Total Income	3,113.67	2,994.65	2,392.78	5,387.43
2. Expense:				
Cost of material consumed	1,787.08	2,036.31	1,580.57	3,616.87
(Increase)/decrease in stock-in-trade	72.37	(97.57)	54.84	(42.73)
Employee benefits expense	404.27	351.14	243.17	594.30
Depreciation, amortization & impairment expense	153.39	113.89	72.83	186.72
Finance costs	136.14	127.29	83.37	210.66
Other expenses	180.02	204.43	168.18	372.61
Total Expenses	2,733.26	2,735.48	2,202.95	4,938.44
3. Profit before Exceptional & Extraordinary Items	380.41	259.17	189.83	448.99
4. Exceptional Item	-	-	-	-
5. Profit Before Extraordinary Items and Tax (3-4)	380.41	259.17	189.83	448.99
6. Extraordinary Items	-	-	-	-
7. Profit before tax (5-6)	380.41	259.17	189.83	448.99
8. Tax Expenses				
(i) Current Tax	56.04	24.48	6.49	30.97
(ii) Deffered Tax	25.81	31.25	23.31	54.56
(iii) Earlier Year Tax	-	-	-	-
9. Profit (Loss) for the Period from continuing operations (7-8)	298.56	203.44	160.02	363.45
10. Profit (Loss) from discontinuing operations	-	-	-	-
11. Tax expense of discontinuing operations	-	-	-	-
12. Profit/ Loss from discontinuing operations(10-11)	-	-	-	-
13. Profit / Loss for the period (9+12)	298.56	203.44	160.02	363.45
Earning Per Equity Share				
(a) Basic (in Rs.)	2.24	1.69	1.36	3.05
(b) Diluted (in Rs.)	2.24	1.69	1.36	3.05

Notes on Standalone Financials Results:

- The above results which are published in accordance with Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements), 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 10 January, 2025.
- As per Ministry of Corporate Affairs Notification dated February 16, 2015, Companies whose securities are Listed on SME Exchange as referred to in Chapter XB of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of Ind AS.
- The figures for the corresponding previous period have been regrouped / reclassified wherever necessary.
- The Company is having one reportable segment i.e. Manufacturing of Pharmaceutical Products such as sterile water ampoule, dry injection, dry syrup.
- KPI in terms of SEBI ICDR Regulations 2018, has been review by the audit committee and approved by the Board. The same is enclosed herewith as annexure - 1.

For and on behalf of the Board of Directors
Onyx Biotec LimitedSanjay Jain
(Managing Director)
DIN: 02214242Date: 10 January, 2025
Place: Chandigarh

ONYX BIOTEC LIMITED

Regd Office: VILLAGE BIR PLASSI, NEAR SAINIMAJRAROPAR, NALAGRH ROAD, Solan, Himachal Pradesh, India, 174101

Website: <https://www.onyxbiotec.com/>, Email: generalinfo@onyxbiotech.com

CIN - L24230HP2005PLC028403

Standalone Cash Flow Statement for the Half Year ended September 30, 2024


(Rs. in Lakhs)

Particulars	September 30, 2024	March 31, 2024
Cash flow from Operating Activities		
Net Profit before tax as per Statement of Profit & Loss	380.41	448.99
Adjustments for :		
- Depreciation, amortization & impairment	153.39	186.72
- Gain on sale of Fixed assets	(95.42)	-
- Interest expenses	136.14	210.66
- Interest income	(2.85)	(7.47)
- Provision for gratuity (unfunded)	59.59	15.65
Operating Profit before Working Capital Changes	631.25	854.54
Changes in Working Capital		
- Change in trade receivables	(288.08)	(1,029.71)
- Change in loans and advances and other assets	50.48	(46.33)
- Change in non current assets	(4.09)	55.50
- Change in inventories	(275.10)	(277.42)
- Change in Provisions	(61.94)	(19.31)
- Change in trade payables	3.68	686.30
- Change in other liabilities	45.28	(71.97)
Net Cash Flow from Operations	101.50	151.61
Less: Income Tax Paid	-	-
Net Cash Flow from Operating Activities (A)	101.50	151.61
Cash Flow from Investing Activities		
Purchase of Fixed Assets	(36.37)	(322.27)
Sale of Fixed Assets	135.09	-
(Purchase) / Sale of Investments	-	-
Movement in Loans & Advances	-	-
Interest Income	2.85	7.47
Net Cash Flow from Investing Activities (B)	101.37	(314.79)
Cash Flow From Financing Activities		
Proceeds / (Repayment) - Partner's Capital	-	-
Proceeds From Share Capital Issue	-	364.56
Proceeds From Share Capital Issue - Share Premium (Net of IPO Exp)	-	-
Interest Repayment	(136.14)	(210.66)
Proceeds / (Repayment) from Long Term Borrowing	(574.39)	557.55
Proceeds / (Repayment) from Short Term Borrowing	512.80	(402.33)
Net Cash Flow from Financing Activities (C)	(197.73)	309.12
Net (Decrease) / Increase in Cash & Cash Equivalents (A+B+C)	5.14	145.94
Opening Cash & Cash Equivalents	146.68	0.74
Cash and Cash Equivalents at the end of the period	151.82	146.68
Cash and Cash Equivalents Comprises:		
Cash in Hand	19.23	1.31
Fixed Deposits	-	-
Bank Balances in Current Account	132.59	145.37
Total	151.82	146.68

Notes:

(i) Figures in brackets are outflows / deductions

(ii) The above Cash Flow Statement is prepared under the indirect method as set out in the Accounting Standards (AS-3) - Statement of Cash Flows

For and on behalf of the Board of Directors
Onyx Biotech Limited

Sanjay Jain
(Managing Director)

DIN: 02214242

Date: 10 January, 2025

Place: Chandigarh

Particulars	Sep-24	Mar-24
Revenue from Operations	3,014.95	5,374.88
EBITDA	669.93	846.37
EBITDA Margin	22.22%	15.75%
Profit After Tax for the Year	298.56	363.45
PAT Margin	9.90%	6.76%
ROE	10.56%	14.37%
ROCE	10.52%	12.79%
Net Debt/ EBITDA	4.50	3.64
Net Debt	3,016.44	3,078.04
EBIT	516.54	659.65
Shareholders fund	2,827.35	2,528.79
Capital Employed	4,908.98	5,159.00

*ROE and ROCE for the period ended Sep 30, 2024 are not annualised, hence, not compareable with March 31, 2024

For ONYX BIOTECH LIMITED

 DIRECTOR